Somatostatin analogs (SSAs) are the most commonly used medical therapy for NETs. SSAs work by binding to somatostatin receptors on the tumor cells, inhibiting hormone release, and slowing tumor growth. Octreotide and lanreotide are the two most commonly used SSAs, and they have been shown to be effective in controlling symptoms and slowing disease progression. These drugs are administered by injection and are generally well-tolerated, with few side effects.
Neuroendocrine Tumor Treatment Market, Another class of drugs used in the treatment of NETs is targeted therapies. Targeted therapies are designed to selectively target specific molecules or pathways that are involved in tumor growth and survival. The most commonly used targeted therapies for NETs are tyrosine kinase inhibitors (TKIs). TKIs work by blocking the activity of specific tyrosine kinases, which are enzymes that promote cell growth and division. Sunitinib and everolimus are the two TKIs currently approved for the treatment of advanced pancreatic NETs, and they have been shown to improve progression-free survival in these patients.
Read More:
https://knackersblogger.blogspot.com/2023/03/global-neuroendocrine-tumor-treatment.html
